2024年9月1日 · Acute myeloid leukemia (AML) is a highly aggressive malignancy of uncontrolled myeloid progenitor cell proliferation and has a dismal survival rate. Despite the availability of standard and targeted therapeutic regimens, the rate of relapse is high in patients when leukemic stem cells (LSCs) are present.

2024年9月1日 · Autophagy and oxidative phosphorylation pathways are significantly altered in AML patients at relapse. These alterations occur at levels of transcription and its regulation during splicing. Our study's future scope is identifying RNA …

2023年11月28日 · We performed mutational profiling, cytogenetic and outcome analyses in 1726 adults with AML (749 female and 977 male) treated on frontline Alliance for Clinical Trials in Oncology protocols. A...

acute myeloid leukemia (AML) poses a significant health burden across the European Union (EU), where variations in incidence, treatment efficacy, and patient outcomes reflect a complex interplay of genetic, environmental, and healthcare factors. Objective: This comprehensive study marks the first estimation of AML’s global

Semantic Scholar extracted view of "AML-749 Regulation of Autophagy and Oxidative Phosphorylation Is Predominantly Altered at the Transcription Level in Leukemic Stem Cells (LSCs) in Relapsed AML" by Aafreen Khan et al.

2014年4月3日 · We report the development of G-749 as a novel FLT3 inhibitor with potent activity against the FLT3-TKD mutants, and its sustained inhibition against FLT3 disease pathways was responsible for potent antileukemic activity via apoptosis in AML cells and patient blasts representing different FLT3 mutation status and even in drug-resistant ...

2024年9月1日 · Central nervous system (CNS) myeloid and lymphoid sarcoma (MS, LS) are uncommon and pose diagnostic and management challenges. Describe the management and outcomes of CNS MS and LS in 4 and 1 patient, respectively. (1) 44-year-old female in blast phase of chronic myeloid leukemia (CML) with altered mental status (AMS) had a …

Denfivontinib (G-749) is a potent, oral active and ATP competitive FLT3 inhibitor, with IC50 s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML) [1].

2014年4月3日 · Aberrant activations of Fms-like tyrosine receptor kinase (FLT) 3 are implicated in the pathogenesis of 20% to 30% of patients with acute myeloid leukemia (AML). G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants including FLT3-ITD, FLT3-D83 …

Autophagy and oxidative phosphorylation pathways are significantly altered in AML patients at relapse. These alterations occur at levels of transcription and its regulation during splicing. Our study's future scope is identifying RNA-binding proteins that regulate these processes.